CO7240393A2 - Composiciones que comprenden un aptámero anti-factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista del factor de crecimiento endotelial vascular (vegf) - Google Patents

Composiciones que comprenden un aptámero anti-factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista del factor de crecimiento endotelial vascular (vegf)

Info

Publication number
CO7240393A2
CO7240393A2 CO14284190A CO14284190A CO7240393A2 CO 7240393 A2 CO7240393 A2 CO 7240393A2 CO 14284190 A CO14284190 A CO 14284190A CO 14284190 A CO14284190 A CO 14284190A CO 7240393 A2 CO7240393 A2 CO 7240393A2
Authority
CO
Colombia
Prior art keywords
growth factor
compositions
pdgf
vegf
platelet
Prior art date
Application number
CO14284190A
Other languages
English (en)
Inventor
Richard Everett
Byeong Seon Chang
Original Assignee
Ophthotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ophthotech Corp filed Critical Ophthotech Corp
Publication of CO7240393A2 publication Critical patent/CO7240393A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a composiciones quecomprenden un aptámero anti-factor de crecimiento derivado deplaquetas (anti-PDGF) y un antagonista del factor decrecimiento endotelial vascular (VEGF). En ciertasmodalidades, las composiciones de la invención son útiles paratratar o prevenir una enfermedad oftálmica.
CO14284190A 2012-06-01 2014-12-26 Composiciones que comprenden un aptámero anti-factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista del factor de crecimiento endotelial vascular (vegf) CO7240393A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261654672P 2012-06-01 2012-06-01
US201361778208P 2013-03-12 2013-03-12

Publications (1)

Publication Number Publication Date
CO7240393A2 true CO7240393A2 (es) 2015-04-17

Family

ID=49674074

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14284190A CO7240393A2 (es) 2012-06-01 2014-12-26 Composiciones que comprenden un aptámero anti-factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista del factor de crecimiento endotelial vascular (vegf)

Country Status (18)

Country Link
US (1) US20150182623A1 (es)
EP (1) EP2854844A4 (es)
JP (1) JP2015519373A (es)
KR (1) KR20150033620A (es)
CN (1) CN104619335A (es)
AR (1) AR091237A1 (es)
AU (1) AU2013267310A1 (es)
CA (1) CA2874412A1 (es)
CL (1) CL2014003233A1 (es)
CO (1) CO7240393A2 (es)
EA (1) EA201492289A1 (es)
HK (1) HK1207983A1 (es)
IL (1) IL235797A0 (es)
MX (1) MX2014014445A (es)
PH (1) PH12014502577A1 (es)
SG (1) SG11201407981RA (es)
TW (1) TW201400122A (es)
WO (1) WO2013181495A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201510315TA (en) 2013-07-12 2016-01-28 Ophthotech Corp Methods for treating or preventing ophthalmological conditions
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3194029A1 (en) * 2014-08-11 2017-07-26 Ophthotech Corporation Methods for treating or preventing ophthalmological conditions
CN105435221B (zh) * 2014-09-22 2021-09-28 正大天晴药业集团股份有限公司 一种针对血管内皮生长因子的人源化抗体的药物组合物
WO2016120753A1 (en) 2015-01-28 2016-08-04 Pfizer Inc. Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
CN105806830B (zh) * 2015-12-10 2019-01-29 北京联众泰克科技有限公司 一种稳定的hrp酶促化学发光底物液、其制备方法及应用
IL260323B1 (en) 2015-12-30 2024-09-01 Kodiak Sciences Inc Antibodies and their conjugates
CA3011638C (en) * 2016-01-26 2023-01-10 Formycon Ag Liquid formulation of a vegf antagonist
WO2017136486A1 (en) * 2016-02-04 2017-08-10 Jinsong Ni Antibody-drug synergism technology for treating diseases
AU2017223687A1 (en) * 2016-02-23 2018-08-09 Sesen Bio, Inc. IL-6 antagonist formulations and uses thereof
US11135266B2 (en) * 2016-11-21 2021-10-05 Just-Evotec Biologics, Inc. Aflibercept formulations and uses thereof
KR101861163B1 (ko) 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
CN111356471A (zh) * 2017-11-20 2020-06-30 济世发展生物药业有限公司 包含赖氨酸盐作为张力调节剂的阿柏西普制剂及其用途
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
WO2019210097A1 (en) * 2018-04-25 2019-10-31 Vitrisa Therapeutics, Inc. Aptamers with stability, potency or half-life for enhanced safety and efficacy
CA3099551A1 (en) 2018-05-10 2019-11-14 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
WO2020087003A1 (en) * 2018-10-26 2020-04-30 Amgen Inc. Formulations comprising a tris buffer and a protein
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
KR20210077645A (ko) * 2019-12-17 2021-06-25 주식회사 프로젠 신규 주사제 제형
JP2023516377A (ja) * 2020-03-04 2023-04-19 上海復宏漢霖生物技術股▲フン▼有限公司 ベバシズマブを含む薬物製剤
KR102690020B1 (ko) * 2020-07-24 2024-08-01 (주)팬젠 안과용 액상 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004268614C1 (en) * 2003-08-27 2010-10-28 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
EP3753548A1 (en) * 2006-06-16 2020-12-23 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
WO2010127029A1 (en) * 2009-05-01 2010-11-04 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
CA2809433A1 (en) * 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof

Also Published As

Publication number Publication date
JP2015519373A (ja) 2015-07-09
MX2014014445A (es) 2015-08-14
KR20150033620A (ko) 2015-04-01
HK1207983A1 (en) 2016-02-19
SG11201407981RA (en) 2015-01-29
EP2854844A2 (en) 2015-04-08
CA2874412A1 (en) 2013-12-05
PH12014502577A1 (en) 2015-01-21
AU2013267310A1 (en) 2014-12-11
US20150182623A1 (en) 2015-07-02
CL2014003233A1 (es) 2015-06-19
WO2013181495A2 (en) 2013-12-05
WO2013181495A3 (en) 2014-02-13
AR091237A1 (es) 2015-01-21
TW201400122A (zh) 2014-01-01
EA201492289A1 (ru) 2015-05-29
EP2854844A4 (en) 2016-11-23
CN104619335A (zh) 2015-05-13
IL235797A0 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
CO7240393A2 (es) Composiciones que comprenden un aptámero anti-factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista del factor de crecimiento endotelial vascular (vegf)
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
FR23C1010I2 (fr) Anticorps bispecifiques anti-ang-2/anti-vegf et leur utilisation dans le traitement des maladies vasculaires oculaires
ECSP15048555A (es) Heterociclos bicíclicos como inhibidores de fgfr
ECSP17062712A (es) Heterociclos bicíclicos como inhibidores de fgfr
DOP2015000216A (es) Inhibidores de bromodominios tetraciclicos
UY34601A (es) ?mezclas fungicidas de pirazol?.
AR092662A1 (es) Anticuerpos anti-ddr1
MX2016002423A (es) Composiciones y metodos de diagnostico para el tratamiento de glioblastoma.
CY1121787T1 (el) Sirna και χρηση αυτων σε μεθοδους και συνθεσεις για τη θεραπεια ή/και προληψη οφθαλμικων καταστασεων
CL2016000055A1 (es) Métodos para tratar o prevenir afecciones oftalmológicas
BR112017023516A2 (pt) composição de polímero reforçado com fibra, e, artigo.
EA201500364A1 (ru) Лечение глазных заболеваний
TN2015000276A1 (fr) Novel compounds
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
CY1117654T1 (el) Πολυαιθυλενογλυκολιωμενη απελινη και χρησεις αυτης
NI201800134A (es) Anticuerpos antifactor de la coagulación xi
UY36171A (es) Derivados heteroaromáticos bicíclicos fusionados como inhibidores de quinasa
DK2964238T3 (da) Abcb5(+) stem cells for treating ocular disease
CL2017001301A1 (es) Composiciones oftálmicas estabilizadas de omega 3
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
EA201600288A1 (ru) Замещенные фенилаланиновые производные
CY1121111T1 (el) Συνθεσεις ανταγωνιστων toy vegf και χρησεις αυτων
MX2015011418A (es) Tratamiento de enfermedades con nanofibras de poli-n-acetilglucosamina.